BRECISE

📍 BRECISE Plenary Meeting – London Another great moment captured from our recent meeting in London 🇬🇧, where partners from across the BRECISE consortium came together to share progress, exchange ideas, and plan the next steps of the project. Following these two days of discussions, we are now collecting inputs, insights, and key takeaways from across all work packages and use cases, and working on organising this content to share it with our community. From scientific advancements to collaborative milestones, there is a lot to unpack, and we look forward to bringing you closer to the work happening within BRECISE. 📢 Stay tuned! More updates, highlights, and partner insights from the meeting will be shared soon. Innovative Health Initiative (IHI) #BRECISE #PrecisionMedicine #CancerResearch #Biomarkers #HorizonEurope #Collaboration #PersonalisedMedicine

🇬🇧 Two Insightful Days with the BRECISE Consortium in London Thank you to all partners for two days full of insightful discussions, collaboration, and progress during the latest BRECISE plenary meeting in London. This first in-person gathering since the kick-off meeting in Madrid last year was an important moment for the consortium to come together again and exchange updates on the work carried out across the project. Over the course of the meeting, we had the opportunity to hear updates from every work package and explore the progress of the five BRECISE use cases, highlighting key milestones achieved so far and discussing the next steps for the months ahead. A big thank you to everyone who joined and contributed to such productive and engaging discussions. Over the coming weeks and months, we will continue sharing insights from the meeting, including dedicated posts on specific work packages and use cases. 🎥 As part of Work Package 7, the communication and dissemination team also recorded a series of interviews with project participants, capturing their perspectives on the progress of BRECISE and its future impact. These insights will be shared soon, so stay tuned! Innovative Health Initiative (IHI), Barbara Vodicska, PhD, Istvan Petak MD, PhD, Farzin Pourfarzad, Justine Fleur V. #BRECISE #PrecisionMedicine #CancerResearch #Biomarkers #HorizonEurope #Collaboration #PersonalisedMedicine

🔬 International Day of Women and Girls in Science Today, we recognise and celebrate the women and girls whose expertise, curiosity, and leadership drive progress in biomarker research and patient-centred healthcare, often behind the scenes, but always at the core of impact. 🌐At BRECISE, we understand that reliable biomarkers are not built by data and technology alone. They are shaped by the people who design studies, validate evidence, interpret results, and translate science into meaningful clinical decisions. Women play a vital role across every stage of this journey. We proudly stand with women in science and support their contributions across research, innovation, and cross-disciplinary collaboration. By fostering inclusive scientific environments, we help strengthen a more robust, equitable, and future-ready precision medicine ecosystem across Europe, one that better reflects the diversity of the patients it aims to serve. #WomenInScience #IDWGS #PrecisionMedicine #Biomarkers #EUResearch

📢 Why Europe’s Biotech Act and BRECISE must now deliver for patients As the BRECISE Consortium prepares for its Annual General Meeting in London (12–13 March), the political and policy context in Europe has shifted decisively. The question facing cancer innovation today is no longer what is possible, but how quickly outcomes can be delivered, and whether they improve patients’ quality of life. The timing of the AGM, aligned with the EAU Congress 2026, is strategic. It places BRECISE at the crossroads of science, clinical practice and policy at a moment when Europe is actively reshaping its innovation ecosystem through the EU Biotech Act. The Biotech Act signals a clear political intent: to strengthen Europe’s capacity to translate cutting-edge research into scalable, investable and sustainable solutions. By simplifying regulatory pathways, boosting access to funding and supporting biomanufacturing and advanced therapeutics, the Act is designed to ensure that innovation does not stall between discovery and deployment. For cancer, and particularly for biomarker-driven approaches in prostate and bladder cancer, this is a pivotal opportunity. Yet investment alone is not enough. What matters is investment in outcomes. Liquid biopsy, molecular diagnostics, AI-enabled pathology and personalised treatment strategies all promise earlier diagnosis, more precise treatment decisions and fewer unnecessary interventions. If implemented well, they can directly improve patients’ quality of life, and not just survival curves. This is where BRECISE’s role becomes critical. Prostate and bladder cancers frequently coexist, share biological drivers and are increasingly shaped by common molecular and hormonal pathways. Treating them in isolation is no longer scientifically defensible, nor economically sustainable. BRECISE’s work on integrated biomarker frameworks, data-driven stratification and cross-disciplinary coordination directly addresses the implementation gap that EU policymakers increasingly recognise as the system’s weakest link. European policy is now converging around this challenge. Europe’s Beating Cancer Plan, the Cancer Mission and the Biotech Act all point in the same direction: faster translation, smarter regulation, and better alignment between innovation and health system readiness. The missing piece is execution, turning pilots into pathways, and evidence into standard care. The London meeting is therefore not a routine consortium meeting, but a working moment: to stress-test interim results, confront regulatory and data barriers, and ensure that BRECISE outputs are implementation-ready. The discussions planned are explicitly intended to feed into wider European debates and decision-making. In 2026, Europe has signalled its ambition. Through the Biotech Act, it has opened the investment door. BRECISE now has the opportunity to help ensure that this momentum translates into better lives for patients, not just better frameworks on paper.

💬 Insights from the BRECISE Kick-Off Meeting | Frans Folkvord on sustainability and real-world impact During the BRECISE Kick-Off Meeting in Madrid 🇪🇸, we spoke with Frans Folkvord, Co-Founder and Director of PredictBy, a key partner supporting the long-term impact of the project. In his interview, he explains how PredictBy contributes across the BRECISE use cases by helping to structure implementation strategies, plan for exploitation, and ensure the sustainability of project outcomes beyond the lifetime of the project. The focus is clear: 🔹 Turn innovation into solutions that can reach the market and healthcare systems 🔹 Ensure biomarker-driven tools developed in BRECISE can benefit patients and clinicians in the long term 🔹 Support more effective and affordable treatments, reducing unnecessary costs while improving care quality By addressing sustainability early on, PredictBy helps ensure that BRECISE does not stop at research, but delivers lasting value for patients, healthcare providers, and society. 🎥 Watch the full interview to learn how sustainability and real-world implementation are built into BRECISE from day one. 👉🏻 Watch here: https://lnkd.in/eRBq3YXu Innovative Health Initiative (IHI), Aimac - Associazione Italiana Malati di Cancro, parenti e amici, Genomate Health, Erasmus MC, Atrys, OHMX.bio, ATS Brianza, Katerina Nikitara, Hellenic Cancer Federation | ELLOK, Tim Hulsen, Ralf Hoffmann, Philips, Davide Guerri, Istvan Petak MD, PhD, Crown Bioscience, Nataliia Beztsinna, BC Platforms, PharmaLedger Association, Denis Horgan, Ph.D, Ana Roca-Umbert Würth, Nick Dietrich, Francisco Lupiañez-Villanueva, Lucas Segal #BRECISE #PredictBy #PrecisionMedicine #Biomarkers #CancerCare #HealthInnovation #Sustainability #HorizonEurope

🎉 A New Year, A New Start: Accelerating Precision Medicine through BRECISE As 2026 begins, a renewed sense of purpose defines the precision medicine community. The coming year will not simply build on past achievements: it will accelerate the translation of biomarker science into clinical reality. At the centre of this momentum stands BRECISE, Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement, a project shaping Europe’s pathway towards a future where cancer care is more predictive, personalized, and patient-focused. BRECISE is more than a research project; it is a blueprint for change. Through its comprehensive methodological framework, BRECISE connects science, regulation, and implementation. It brings together 31 public and private partners, spanning biotechnology, academia, clinical practice, patient advocacy, and regulatory science, to align on one critical goal: making validated biomarkers a cornerstone of precision oncology. The project’s work in prostate and bladder cancer embodies this vision. By clinically validating four next-generation biomarkers from PDE4D7 for active surveillance in prostate cancer to NOVI I/O BC for response prediction in metastatic bladder cancer — BRECISE is bridging the gap between discovery and adoption. Its integration of artificial intelligence, multimodal analytics, and ex vivo testing reflects a pragmatic commitment: innovation that delivers measurable benefit to patients and health systems alike. The transition from theory to practice is underway. With its regulatory engagement strategy, GDPR-compliant data integration platform, and a roadmap that embraces education, dissemination, and training, BRECISE is defining how biomarkers will move from the laboratory bench to the clinical front line. This is not just a technical achievement, it is a collaborative movement to make healthcare smarter, faster, and fairer. 🗓️ That spirit of collaboration will take centre stage at the BRECISE Plenary, to be held in London on 12–13 March 2026. While good weather cannot be guaranteed, one thing is certain: the discussions will be rich, relevant, and impactful. The Plenary will gather leading voices from research, regulation, and patient advocacy to chart the next steps in biomarker readiness and clinical integration. A new year, a new start and a shared determination to turn precision medicine from promise to practice. BRECISE will be leading the way. #IHI #BRECISE

💬 Insights from the BRECISE Kick-Off Meeting | Davide Guerri on Dedalus Italy’s role in Use Case 5 During the BRECISE Kick-Off Meeting in Madrid 🇪🇸, we spoke with Davide Guerri from Dedalus Italy, one of the key partners contributing to the project’s clinical and digital innovation. In this interview, Davide Guerri shares how Dedalus Italy, together with ATS Brianza, is leading Use Case 5, the prototype-driven use case within BRECISE. This use case focuses on developing practical digital solutions that can support clinicians in their daily decision-making and help translate biomarker insights into real clinical workflows. Davide explains how this work aims to: 🔹 Support clinicians in better addressing and treating prostate cancer 🔹 Enable a more personalised and patient-centred approach to care 🔹 Help citizens and patients benefit from clearer, more targeted clinical pathways By connecting technology, clinical practice, and real-world healthcare needs, Dedalus Italy’s contribution helps ensure that BRECISE innovations are not only scientifically sound, but also usable and impactful in everyday care. 🎥 Watch the full interview to learn more about Use Case 5 and Dedalus Italy’s role within BRECISE. 👉 Watch here: https://lnkd.in/dsscGzKW Aimac - Associazione Italiana Malati di Cancro, parenti e amici, Hellenic Cancer Federation | ELLOK, Genomate Health, PredictBy, OHMX.bio, Tim Hulsen, Istvan Petak MD, PhD, Katerina Nikitara, Walton Institute, Erasmus MC, Philips, Ralf Hoffmann, BioClavis Ltd, Crown Bioscience, Nataliia Beztsinna, Atrys, Laura Pinna (PhD), BC Platforms, PharmaLedger Association, Melina Genovese, Davide Di Giorgi, Maria Morena Valzano, Tahlita Zuiverloon, Juan Ignacio Barrasa López (PhD, MsC), Frans Folkvord, Denis Horgan, Ph.D, European Alliance for Personalised Medicine (EAPM) #BRECISE #Dedalus #PrecisionMedicine #DigitalHealth #CancerCare #ProstateCancer #Biomarkers #Oncology #HealthInnovation #HorizonEurope

💬 Patient Voices at the Centre | Laura del Campo on AIMAC’s role in BRECISE During the BRECISE Kick-Off Meeting in Madrid 🇪🇸, we spoke with Laura Del Campo, Director of Aimac - Associazione Italiana Malati di Cancro, parenti e amici, who brought a vital perspective to our discussions: the voice of patients and caregivers. In her interview, she highlights AIMAC’s core mission: providing clear, personalised, and accessible information to people living with cancer and their families. Within BRECISE, AIMAC plays a key role in ensuring that communication around biomarkers, clinical decisions, and emerging diagnostic tools is understandable, accurate, and truly patient-centered. AIMAC’s contribution helps BRECISE: 🔹 Integrate patient and caregiver needs into biomarker research 🔹 Ensure ethical standards and transparency in communication 🔹 Raise public awareness of personalised medicine and its potential benefits 🔹 Keep the human dimension at the heart of scientific innovation 🎥 Watch Laura del Campo’s full interview to hear how AIMAC is helping BRECISE make biomarker-driven precision oncology more meaningful and accessible for those who need it most. 👉 Watch here: https://lnkd.in/eSW4Cr_G OHMX.bio, PredictBy, Dedalus, Erasmus MC, ATS Brianza, Hellenic Cancer Federation | ELLOK, Denis Horgan, Ph.D, Tim Hulsen, Juan Ignacio Barrasa López (PhD, MsC), Katerina Nikitara, Davide Guerri, Crown Bioscience, Nataliia Beztsinna, Frans Folkvord, Istvan Petak MD, PhD, Genomate Health, BioClavis Ltd, Atrys, BC Platforms, Novigenix SA, PharmaLedger Association, 3D-PharmXchange #BRECISE #AIMAC #PatientAdvocacy #CancerCare #CancerSupport #PrecisionMedicine #Biomarkers #Oncology #PersonalisedMedicine #HealthCommunication #HorizonEurope

💬 BRECISE at Vision Europe 2030 | Insights from Xenia Beltrán on Biomarkers & Precision Oncology During VISION EUROPE 2030, the two-day conference in Brussels organised by European Alliance for Personalised Medicine (EAPM), BRECISE was proudly represented by Xenia Beltrán, Program Manager at BRIDG-OU and Public Coordinator of the project. In her interview, she highlighted how BRECISE is helping shape the future of precision oncology through the development and validation of next-generation biomarkers for prostate and bladder cancer. She emphasized: 🔹 The critical role of cross-sector collaboration in tackling major health challenges like cancer 🔹 How biomarkers are reshaping medicine—moving from prognosis to truly predictive and personalised care 🔹 Her involvement not only in BRECISE but also in ENACT, two projects advancing biomarker development for urological cancers and studying environmental influences on human health 🔹 Why Europe must continue strengthening international cooperation to build resilient and equitable health systems Xenia Beltran’s comments underline the ambition at the heart of BRECISE: turning scientific potential into real-world impact by building an integrated, collaborative framework for biomarker-driven precision medicine. 🎥 Watch the full interview here: https://lnkd.in/es-k2aAV Aimac - Associazione Italiana Malati di Cancro, parenti e amici, Laura Del Campo, Genomate Health, Istvan Petak MD, PhD, PredictBy, Tim Hulsen, Hellenic Cancer Federation | ELLOK, George Kapetanakis, Katerina Nikitara, Nataliia Beztsinna, Crown Bioscience, Walton Institute, 3D-PharmXchange, Juan Ignacio Barrasa López (PhD, MsC), Dedalus, Davide Guerri, Philips, Denis Horgan, Ph.D, Karolinska University Hospital, ATS Brianza, OHMX.bio, Atrys, Ralf Hoffmann, Frans Folkvord, Atefeh Sadeghi, Jordi Lli Beltrán, Innovative Health Initiative (IHI) #BRECISE #VisionEurope2030 #PrecisionMedicine #Biomarkers #CancerResearch #Oncology #HorizonEurope #IHI #HealthInnovation #PersonalisedMedicine #EAPM #HaDEA

💬 Nataliia Beztsinna’s insights during BRECISE’s Kick-Off Meeting | Crown Bioscience on bridging research and real-world care During the BRECISE Kick-Off Meeting in Madrid 🇪🇸, we had the pleasure of speaking with Nataliia Beztsinna, Director of Scientific Engagement at Crown Bioscience, one of the key partners in the BRECISE consortium. In her interview, she explores how Crown Bioscience contributes to advancing precision oncology through ex vivo testing — a method that studies how tumour samples respond to treatments outside the body. She discusses how this approach: ✅ Helps identify whether predictive biomarker signatures truly translate into drug responses ✅ Supports clinicians in tailoring therapies for each patient, especially in high-risk prostate cancer ✅ Bridges the gap between preclinical research and real-world clinical outcomes 🎥 Watch the full interview to discover how Crown Bioscience’s expertise is helping BRECISE move biomarker science from the lab to the clinic. 👉 Watch here: https://lnkd.in/eH48Af3u Aimac - Associazione Italiana Malati di Cancro, parenti e amici, Genomate Health, 3D-PharmXchange, OHMX.bio, ATS Brianza, Dedalus, Philips, PredictBy, Hellenic Cancer Federation | ELLOK, Katerina Nikitara, Ilaria Chicca, Ralf Hoffmann, Gary McManus, Walton Institute, Juan Ignacio Barrasa López (PhD, MsC), Shannon Kouters, Sander Basten, PhD, BioClavis Ltd, Atrys, Tim Hulsen, Denis Horgan, Ph.D, BC Platforms, PharmaLedger Association, Istvan Petak MD, PhD, Innovative Health Initiative (IHI) #BRECISE #CrownBioscience #PrecisionMedicine #CancerResearch #Oncology #Biomarkers #HealthInnovation #HorizonEurope #PersonalisedMedicine